bms 1

BMS-1 (PD-1/PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.

LIMK1 inhibitor BMS-4 is a compound targeting LIM Kinase (LIMK) 1/2, specifically inhibiting the phosphorylation of its substrate cofilin, while remaining noncytotoxic on A549 cells.

BMS 183920 is a potent Angiotensin II Receptor antagonist that improves improves Caco-2 cell permeability in vivo.

BMS 193885 is a selective and competitive neuropeptide Y(1) receptor antagonist with affinity of 3.3 nM.

BMS 182874 hydrochloride is a nonpeptide endothelin (El) receptor antagonist.

BMS 195614 (BMS614) is a selective RARα antagonist. BMS 195614 can bind to the RARα subunit.

BMS 180742 is an exosite inhibitor of thrombin.

BMS 182874 is an orally effective and highly selective endothelin receptor ETA antagonist with an IC50 value of 0.150 μM for ETA and a Ki value of 0.055 μM for ETA.BMS 182874 is able to reduce arterial pressure in a rat hypertension model induced by Deoxycorticosterone acetate. BMS 182874 was able to reduce Deoxycorticosterone-induced arterial pressure in a rat model of hypertension and can be used to study cardiovascular disease.

Bms 188107 is a calcium antagonist, it has cardioprotective effects.

BMS 199264 hydrochloride is the salt form of BMS 199264.BMS 199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase (IC50=0.5 μM) without affecting ATP synthetase, thus preventing ATP reduction to ameliorate cardiac necrosis during ischemia, and is commonly used in studies of the cardiovascular system.

BMS 180448 is a prototype mitochondrial ATP-sensitive K+ (Mitok (ATP)) channel opener with cardioprotective and vasodilating properties.

BMS 180680 is a novel catechol-containing monolactam antibacterial active agent, which is the most effective compound against many species of Enterobacteriaceae.

BMS-181101 is a novel antidepressant that has pharmacological characteristics as a serotonin reuptake inhibitor and a serotonin 5-HT receptor agonist.

BMS 182264 is a bio-active chemical.

BMS 186318 is a human immunodeficiency virus (HIV) protease inhibitor designed to examine the possibility of developing resistance when two protease inhibitors are used together in recombination.

BMS 187071 is a bio-active chemical.

BMS 188745 Potassium Salt inhibits the biosynthesis of the Staphylococcus aureus virulence factor staphyloxanthin via inhibition of dehydrosqualene synthase (CrtM).

BMS-1166-n-piperidine-co-n-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1/PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1/PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1/PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.

Gemopatrilat is a an vasopeptidase inhibitor.

BMY-21502 is a potential cognitive enhancer that shows anti-hypoxia effects in the KCN-hypoxia model, delays the decay of hippocampal synaptic enhancement in vitro, and can be used to study Alzheimer's disease.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

BMS-199264 hydrochloride is the salt form of BMS-199264.BMS-199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase with an IC50=0.5 μM.BMS-199264 is able to inhibit the decline of ATP during myocardial ischemia, reduce myocardial necrosis, and enhance the recovery of myocardial contractile function after reperfusion.

BMY-14802 hydrochloride (BMS 181100 hydrochloride) is a selective antagonist of σ receptor (IC50 = 112 nM) with antipsychotic effects. BMY-14802 hydrochloride is an agonist of the α1-adrenergic receptor and 5-HT1A.

BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 is capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.